Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology

Effective anticancer treatments have dramatically improved the outcome of patients with cancer, but cardiac toxicity reduces their clinical efficacy in a non-negligible percentage of patients. Sacubitril/valsartan is a new paradigm in the treatment of chronic heart failure, with a reduced ejection f...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cardiovascular medicine 2022-03, Vol.9, p.801143
Main Authors: Canale, Maria Laura, Coviello, Katia, Solarino, Gianluca, Del Meglio, Jacopo, Simonetti, Federico, Venturini, Elio, Camerini, Andrea, Maurea, Nicola, Bisceglia, Irma, Tessa, Carlo, Casolo, Giancarlo
Format: Article
Language:English
Subjects:
anthracyclines
cardio-oncology
Cardiovascular Medicine
heart failure
sacubitril/valsartan
wearable cardioverter defibrillator
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Effective anticancer treatments have dramatically improved the outcome of patients with cancer, but cardiac toxicity reduces their clinical efficacy in a non-negligible percentage of patients. Sacubitril/valsartan is a new paradigm in the treatment of chronic heart failure, with a reduced ejection fraction due to the enhancement of natriuretic peptides' properties when coupled with a blocking effect on the angiotensin II type 1 (AT1) receptors. As with other clinical conditions of heart failure with potentially reversible declines in cardiac function, a wearable cardioverter defibrillator (WCD) is a valid tool for protection against sudden death until recovery occurs. We report a case series of four patients with chemotherapy-related acute cardiac failure with severely reduced cardiac function. They were successfully treated with sacubitril/valsartan while being protected from malignant arrhythmias using a wearable cardioverter defibrillator until the recovery of cardiac function. Sacubitril/valsartan was confirmed to be effective in anthracycline-related cardiac toxicity and the wearable cardioverter defibrillator should be considered as a support tool even in the oncology patient.
ISSN:2297-055X
2297-055X
DOI:10.3389/fcvm.2022.801143